Paul Elliot Mann Sells 83,758 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Paul Elliot Mann sold 83,758 shares of ASP Isotopes stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $8.29, for a total transaction of $694,353.82. Following the sale, the chief executive officer owned 9,663,424 shares of the company’s stock, valued at $80,109,784.96. The trade was a 0.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paul Elliot Mann also recently made the following trade(s):

• On Wednesday, June 3rd, Paul Elliot Mann sold 83,759 shares of ASP Isotopes stock. The shares were sold at an average price of $7.76, for a total value of $649,969.84.

ASP Isotopes Price Performance

Shares of NASDAQ ASPI opened at $7.97 on Friday. The business’s 50 day moving average price is $5.50 and its 200 day moving average price is $5.87. The firm has a market cap of $1.00 billion, a P/E ratio of -3.83 and a beta of 3.42. The company has a quick ratio of 4.37, a current ratio of 4.39 and a debt-to-equity ratio of 0.69. ASP Isotopes Inc. has a 52 week low of $3.92 and a 52 week high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings data on Wednesday, May 20th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. The firm had revenue of $8.36 million for the quarter, compared to analyst estimates of $3.68 million. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%.

Hedge Funds Weigh In On ASP Isotopes

Hedge funds have recently bought and sold shares of the business. State of Wyoming acquired a new stake in ASP Isotopes in the first quarter valued at approximately $29,000. Quantbot Technologies LP acquired a new position in shares of ASP Isotopes during the 3rd quarter worth approximately $34,000. BNP Paribas Financial Markets raised its stake in shares of ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after buying an additional 2,548 shares during the period. Stephens Inc. AR purchased a new position in shares of ASP Isotopes during the 1st quarter valued at approximately $44,000. Finally, Broadhurst Jeffrey B purchased a new position in shares of ASP Isotopes during the 1st quarter valued at approximately $44,000. Hedge funds and other institutional investors own 16.80% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ASPI shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 target price on shares of ASP Isotopes in a report on Tuesday, April 14th. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, ASP Isotopes has a consensus rating of “Hold” and an average price target of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.